{"abstract": "Gilead Sciences reported $2.3 billion in sales of Sovaldi, a new hepatitis C drug that has raised an outcry over its $1,000-a-pill price.", "web_url": "https://www.nytimes.com/2014/04/23/your-money/gilead-revenue-soars-on-hepatitis-c-drug.html", "snippet": "Gilead Sciences reported $2.3 billion in sales of Sovaldi, a new hepatitis C drug that has raised an outcry over its $1,000-a-pill price.", "lead_paragraph": "Record sales of a new hepatitis C drug pushed the first-quarter earnings of Gilead Sciences far beyond expectations, the company reported on Tuesday, but could also heighten concerns about the high cost of the drug, known as Sovaldi, and the ability of the health care system to pay for it.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/gilead/gilead-articleLarge-v2.jpg", "height": 773, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/22/business/gilead/gilead-articleLarge-v2.jpg", "xlargewidth": 600, "xlargeheight": 773}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/gilead/gilead-jumbo-v2.jpg", "height": 1024, "width": 796, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/gilead/gilead-superJumbo-v2.jpg", "height": 2048, "width": 1591, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/gilead/gilead-thumbStandard-v2.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/22/business/gilead/gilead-thumbStandard-v2.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/gilead/gilead-thumbLarge-v2.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Gilead Revenue Soars on Hepatitis C Drug", "kicker": null, "content_kicker": null, "print_headline": "Gilead Revenue Soars on Hepatitis C Drug", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Gilead Sciences Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 2, "major": "N"}, {"name": "subject", "value": "Sovaldi (Drug)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Company Reports", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Hepatitis", "rank": 6, "major": "N"}], "pub_date": "2014-04-22T22:17:46+0000", "document_type": "article", "news_desk": "Business", "section_name": "Your Money", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/a232c47d-c41e-5bdf-a6b2-f2657a16fce3", "word_count": 926, "uri": "nyt://article/a232c47d-c41e-5bdf-a6b2-f2657a16fce3"}